Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Adding stomach scope to colonoscopy: worth the cost?

NCT ID NCT07522320

Knowledge-focused Sponsor: Unidade Local De Saúde Do Norte Alentejano Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study examines the extra costs of doing an upper endoscopy (stomach scope) at the same time as a routine colonoscopy for colon cancer screening. Researchers will also analyze the overall economic burden of treating stomach cancer. Data from 250 patients will be collected from hospital records to understand costs, treatment patterns, and survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Cohort A - Opportunistic screening cohort A cohort of FIT-positive individuals undergoing colonoscopy for colorectal cancer screening, with the addition of opportunistic EGD during the same procedure. Cohort B - Gastric cancer cohort A retrospective cohort including all patients diagnosed with gastric adenocarcinoma in the institution over a 11-year period.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Cohort A: * Eligible participants were adults aged 50 to 75 years or older who had been referred for colonoscopy as part of the national colorectal cancer screening programme, following a positive FIT. To be included, individuals also needed to provide informed consent and agree to undergo an EGD endoscopy for the screening of potential upper gastrointestinal precancerous conditions or lesions. Cohort B: * Patients with gastric adenocarcinoma, diagnosed and treated at Unidade Local de Saúde do Alto Alentejo between 2015 and 2025. Exclusion Criteria: Cohort A: * Exclusion criteria included a prior diagnosis of gastric cancer, as well as any condition that would prevent the safe performance of the EGD or the collection of gastric mucosal biopsies. Previous EGD was not listed as an exclusion criterion. Cohort B: * Other types of gastric tumors. * Gastric involvement from metastatic disease of another primary tumor.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric adenocarcinoma Gastric cancer (GC)

Contacts and locations

Locations

  • Unidade Local de Saúde do Alto Alentejo

    Portalegre, 7300-060, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.